About: Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
Creator	Barbieri, Michelangela Bergamaschi, Luca Biffi, Mauro Concetta D'angelo, Emanuela Coppola, Nicola Galié, Nazzareno Maggi, Paolo Marfella, Raffaele Messina, Vincenzo Paolisso, Giuseppe Paolisso, Pasquale Pizzi, Carmine Rizzo, Maria Sardu, Celestino Viale, Pierluigi
Source	Elsevier; Medline; PMC
abstract	Abstract Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influenced the outcomes of diabetes patients with infectious diseases. Of the 475 Covid-19-positive patients admitted to infectious disease departments (University of Bologna, University Vanvitelli of Napoli, San Sebastiano Caserta Hospital) in Italy since 1 March 2020, 31 (39.7%) hyperglycaemic and 47 (60.3%) normoglycaemic patients (blood glucose levels ≥ 140 mg/dL) were retrospectively evaluated at admission and during their hospital stay. Of note, 20 (64%) hyperglycaemic and 11 (23.4%) normoglycaemic patients had diabetes (P < 0.01). At admission, hyperglycaemic vs normoglycaemic patients had fivefold higher IL-6 levels, which persisted even after TCZ administration (P < 0.05). Intriguingly, in a risk-adjusted Cox regression analysis, TCZ in hyperglycaemic patients failed to attenuate risk of severe outcomes as it did in normoglycaemic patients (P < 0.009). Also, in hyperglycaemic patients, higher IL-6 plasma levels reduced the effects of TCZ, while adding IL-6 levels to the Cox regression model led to loss of significance (P < 0.07) of its effects. Moreover, there was evidence that optimal Covid-19 infection management with TCZ is not achieved during hyperglycaemia in both diabetic and non-diabetic patients. These data may be of interest to currently ongoing clinical trials of TCZ effects in Covid-19 patients and of optimal control of glycaemia in this patient subset.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1016/j.diabet.2020.05.005
bibo:pmid	32447102
has license	els-covid
sha1sum (hex)	b0c040179aeccbb845778952ddb9132d982cd7e1
schema:url	https://doi.org/10.1016/j.diabet.2020.05.005
resource representing a document's title	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
has PubMed Central identifier	PMC7241396
has PubMed identifier	32447102
schema:publication	Diabetes Metab
resource representing a document's body	covid:b0c040179aeccbb845778952ddb9132d982cd7e1#body_text
is schema:about of	named entity 'patients' named entity 'tocilizumab' named entity 'patients' named entity 'hyperglycaemia' named entity 'therapy' named entity 'pneumonia' named entity 'influenced' named entity 'patients' named entity 'cytokine' named entity 'homoeostasis' named entity 'Tocilizumab' named entity 'glucose' named entity 'tocilizumab' named entity 'Covid-19' named entity 'hyperglycaemia' named entity 'tocilizumab' named entity 'cytokine' named entity 'IL-2' named entity 'insulin' named entity 'prognostic factor' named entity 'diabetes' named entity 'plasma levels' named entity 'HbA1c' named entity 'loss of significance' named entity 'insulin therapy' named entity 'T-cell' named entity 'CRS' named entity 'hyperglycaemic' named entity 'Cox regression' named entity 'insulin' named entity 'IL-6' named entity 'serum concentrations' named entity 'hyperglycaemia' named entity 'IL-6' named entity 'diabetes' named entity 'hyperglycaemic' named entity 'fasting plasma glucose' named entity 'infection' named entity 'hyperglycaemia' named entity 'lungs' named entity '0.01' named entity 'subcutaneous' named entity 'non-diabetic' named entity 'autoimmune' named entity 'pneumonia' named entity 'IL-6' named entity 'hyperglycaemia' named entity 'dendritic cells' named entity 'pneumonia' named entity 'hypoxia' named entity 'Covid' named entity 'hypoglycaemic' named entity 'IL-6' named entity 'macrophage' named entity 'mg/dL' named entity 'airway' named entity 'acute inflammation' named entity 'regression analysis' named entity 'diabetes' named entity 'cytokine' named entity 'Interleukin-6' named entity 'IL-6' named entity 'IL-6' named entity 'acute illness' named entity 'diabetes' named entity 'acute myocardial infarction' named entity 'diabetes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software